Dario Demonstrates 12 Months of Sustained Healthy Behavior Change for Members Taking a GLP-1
New research presented by DarioHealth at the 84th Annual ADA Scientific Sessions demonstrates the efficacy of their digital health platform in sustaining behavior change for members taking GLP-1 medications. Data over a 12-month period show significant improvements in healthy lifestyle tracking and blood glucose control. Notably, 31% of Type 2 diabetes members achieved results consistent with diabetes remission. This research underscores the importance of combining GLP-1 medications with effective digital health solutions to maximize outcomes.
- The research shows that Dario's platform supports sustained behavior change over 12 months.
- 31% of Type 2 diabetes members achieved diabetes remission, demonstrating significant impact.
- Dario members on GLP-1 medications saw a significant reduction in blood glucose levels within the first 5 months, maintained throughout the year.
- Members showed increased engagement in recording healthy lifestyle activities, including meal logging and physical activity.
- 70% of members achieved blood glucose levels of less than 140 mg/dL in their last month of usage.
- None.
Insights
The recent findings presented by DarioHealth could have substantial implications for its financial performance. The sustained healthy behavior change among members using the Dario platform alongside GLP-1 medications demonstrates the effectiveness and stickiness of Dario's digital health solutions. This could result in greater customer retention and potentially higher recurring revenue, as individuals and healthcare providers may continue to invest in Dario's services.
Additionally, the achievement of diabetes remission by 31% of the participants is significant. If Dario can continue to showcase these outcomes, it could lead to an increase in demand for its platform from both individuals managing Type 2 diabetes and from insurance companies looking to cut long-term healthcare costs. This could potentially improve Dario's market position and provide a competitive edge.
In the short term, these positive outcomes could enhance investor confidence and drive up the stock price. Over the longer term, consistent clinical results combined with market acceptance could pave the way for sustainable revenue growth and potentially profitability. However, investors should remain cautious about over-reliance on these findings until they see consistent performance over time and broader market adoption.
The research presented by DarioHealth at the ADA conference showcases notable clinical progress. Sustaining healthy behavior over a 12-month period indicates that Dario's platform is effectively engaging users, which is critical in chronic disease management. The enhanced outcomes for members using GLP-1 medications, including reduced blood glucose levels and increased weight monitoring, highlight the platform's potential to complement pharmacotherapy effectively.
Furthermore, the achievement of diabetes remission by 31% of Dario users is an encouraging finding. Remission in Type 2 diabetes is a challenging goal and Dario's ability to aid such a significant portion of its users in reaching this goal demonstrates the platform's potential clinical benefits. This positions DarioHealth as a valuable tool in the broader landscape of diabetes management, potentially influencing clinical practice guidelines.
However, it is important to note that this is retrospective data. Prospective, randomized controlled trials would provide more robust evidence of the platform's efficacy. Additionally, further research is needed to understand the long-term sustainability of these behavior changes and their ultimate impact on diabetes management and complications.
New research confirms behavior change driven by Dario digital platform is sustainable for 12 month period and supports clinical results for members taking a GLP-1
Additional research demonstrates
Adopting healthy behaviors while taking a GLP-1 is crucial for the efficacy of the drug. The sustainability of these behaviors is proven to be achievable through the innovative technology behind Dario's cardiometabolic solution and integrated tools for GLP-1 medications. Sustainable behavior change allows users to continue to realize healthy outcomes after offboarding the drug.
"This new research shows there is tremendous value in giving people a digital health solution designed for behavior change alongside GLP-1 medications. We are excited to see this early data reinforce what we have seen in general member population: our highly personalized approach to behavior change works," said Yifat Hershcovitz, PhD., Vice President of Clinical and Scientific Affairs at Dario.
"Standards of care for cardiometabolic health are evolving thanks to new GLP-1 medications, but research, including Dario's newest study, continues to demonstrate the importance of effective behavior change. These medications require the meaningful and sustainable change that Dario delivers for our members and our clients to support full realization of the value of these drugs," said Omar Manejwala, M.D., Chief Medical Officer.
Dario Members Sustain Healthy Behaviors for 12 Months Alongside While Taking a GLP-1
To understand how Dario can best support members taking a GLP-1, a retrospective analysis was conducted using data from members using Dario to manage Type 2 diabetes or prediabetes and taking either Metformin, a standard medication prescribed for diabetes, or a GLP-1. Both member groups were tracked for 12 months as they engaged with Dario's digital chronic condition solution to measure blood glucose levels and track lifestyle activities such as diet and exercise. Members also utilized Dario's Medication Cabinet feature to log Metformin or GLP-1 dataset reminders and report adherence.
The data showed significant improvement in adopting healthy behaviors over a 12-month period across both groups as shown by increased tracking of healthy lifestyle behaviors as shown by logged meals and physical activity beginning in the first three months and sustained through the 12-month period.
Dario members using a GLP-1 also experienced additional improvements to outcomes and behavior change compared to the group using Metformin:
- Dario members using a GLP-1 experienced a significant reduction in blood glucose levels in the first 5 months with the changes sustained through the rest of the year
- Dario members using a GLP-1 demonstrated a significant increase in the monthly number of weight measurements over 12 months
Additional research presented by Dario at the ADA conference examined Dario's ability to help members realize the goal of diabetes remission for people living with Type 2 diabetes. The ADA considers remission to be achieve when an individual with Type 2 diabetes sustains normal blood glucose levels of less than
This retrospective study analyzed the data of 7,240 individuals with Type 2 diabetes using Dario to help manage their condition without the help of insulin for at least six months. The results demonstrated a significant impact:
31% of Dario members experienced blood glucose levels reflecting the goal of diabetes remission with average blood glucose readings of less than 140 mg/dL (A1c6.5% ) during a three-month period70% of Dario members achieved a blood glucose level of less than 140 mg/dL in their last month of usage maintained it for three-month period, indicating behavior change and improved long-term glycemic control- Lifestyle activities as shown by logged meals and physical activity moderated the reduction in average blood glucose levels and high readings ratio.
"Diabetes remission is becoming a more popular goal for people living with Type 2 diabetes as more clinicians and people realize the immense benefits to their overall health. This new research shows that when we empower people with the right solution, we are giving them the ability to do so much more than control their blood glucose; they are able to make incredibly hard changes to accomplish their health goals," said Yifat Hershcovitz, PhD., Vice President of Clinical and Scientific Affairs at Dario.
"This data is incredibly exciting and confirming of our approach at Dario. We want every member to find value in Dario, and for those who seek remission of their Diabetes, we can confidently say we can help them achieve this goal. This is also extremely important for our clients as we can demonstrate once again that our highly personalized approach to engagement delivers best-in-class outcomes to support chronic condition management goals," said Omar Manejwala, M.D., Chief Medical Officer, Dario.
1 Riddle MC, Cefalu WT, Evans PH, Gerstein HC, Nauck MA, Oh WK, Rothberg AE, Le Roux CW, Rubino F, Schauer P, Taylor R, Twenefour D. Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. Diabetes Care 2021 Oct 1;44(10):2438–2444. doi: 10.2337/dci21-0034
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.
Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the benefit of its platform and products, including in the management of chronic conditions and the potential for Diabetes remission. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the
DarioHealth Corporate Contact
Mary Mooney
VP Marketing
+1-312-593-4280
DarioHealth Investor Relations Contact
Kat Parrella
Investor Relations Manager
kat@dariohealth.com
+ 315-378-6922
Media Contact
Scott Stachowiak
Scott.Stachowiak@russopartnersllc.com
+1-646-942-5630
Logo: https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/dario-demonstrates-12-months-of-sustained-healthy-behavior-change-for-members-taking-a-glp-1-302181476.html
SOURCE DarioHealth Corp.
FAQ
What did the DarioHealth study presented at the 84th ADA Scientific Sessions find?
How effective is DarioHealth's digital platform for Type 2 diabetes members?
What improvements did Dario members on GLP-1 medications experience?
What percentage of Dario's Type 2 diabetes members achieved diabetes remission?
What were the key findings from DarioHealth's research presented in June 2024?
